News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
For media inquiries, contact us at media@compasspathways.com
To make sure it is safe and effective in patients, psilocybin therapy needs to be approved by medical regulators, not legislators.
January 08, 2020
Why do we seek patent protection?
The cost of developing psilocybin therapy, with clinical trials in multiple countries, is significant, and involves considerable risk and resource. We think it’s an investment worth making.
January 08, 2020
How will we make psilocybin therapy accessible to all who need it, not just those who can afford it?
Psilocybin therapy is unusual because it’s an innovative protocol that combines a medicine with psychological support.
January 08, 2020
What is our policy on Open Science and how do we work with independent researchers?
Here we explain our full commitment to Open Science, including publishing the results from all our trials and supporting the publication of all results from independent studies that use our psilocybin.
January 07, 2020
How do we train our therapists and do we require them to have personal experience with psilocybin?
Our therapist training programme has been designed by experts from the fields of psychology, psychiatry and psychedelic therapy research.